Conversely, long-term oxaliplatin treatment in both gastric carcinoma cells and organoids reduces SLFN11 expression, causing oxaliplatin resistance that is reversed by reactivation of SLFN11 (with epigenetic modifying drugs). This evidence concerns the gene SLFN11 and gastric carcinoma.